Logo image
Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials
Journal article   Open access   Peer reviewed

Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials

Ahmed Lotfy, Noha M AboQuella and Hongjun Wang
Stem cell research & therapy, Vol.14, p.66
04/07/2023
PMID: 37024925
Web of Science ID: WOS:000963455700005

Abstract

Cell- and Tissue-Based Therapy Exosomes Extracellular Vesicles Immunomodulation Mesenchymal Stem Cells Biomedical Research (Multidisciplinary) Clinical Research or Studies
Mesenchymal stromal/stem cells (MSCs) are widely utilized in cell therapy because of their robust immunomodulatory and regenerative properties. Their paracrine activity is one of the most important features that contribute to their efficacy. Recently, it has been demonstrated that the production of various factors via extracellular vesicles, especially exosomes, governs the principal efficacy of MSCs after infusion in experimental models. Compared to MSCs themselves, MSC-derived exosomes (MSC-Exos) have provided significant advantages by efficiently decreasing unfavorable adverse effects, such as infusion-related toxicities. MSC-Exos is becoming a promising cell-free therapeutic tool and an increasing number of clinical studies started to assess the therapeutic effect of MSC-Exos in different diseases. In this review, we summarized the ongoing and completed clinical studies using MSC-Exos for immunomodulation, regenerative medicine, gene delivery, and beyond. Additionally, we summarized MSC-Exos production methods utilized in these studies with an emphasis on MSCs source, MSC-Exos isolation methods, characterization, dosage, and route of administration. Lastly, we discussed the current challenges and future directions of exosome utilization in different clinical studies as a novel therapeutic strategy.
url
Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trialsView
Published (Version of record) link to article Open CC BY V4.0

Related links

Details

Logo image